Insmed (INSM) Liabilities and Shareholders Equity (2010 - 2026)

Insmed's Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $2.1 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 15.15% year-over-year to $2.1 billion; the TTM figure through Mar 2026 stood at $9.2 billion (up 19.37% YoY), while the FY2025 annual figure was $2.3 billion, up 11.82% from the prior year.
• Liabilities and Shareholders Equity was $2.1 billion for Q1 2026 at Insmed, down from $2.3 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $2.5 billion in Q2 2025 to a low of $994.8 million in Q3 2022.
• Historically, Liabilities and Shareholders Equity has averaged $1.7 billion across 5 years, with a median of $1.7 billion in 2022.
• Biggest YoY gain for Liabilities and Shareholders Equity was 66.57% in 2022; the steepest drop was 24.16% in 2022.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.7 billion in 2022, then retreated by 19.72% to $1.3 billion in 2023, then surged by 52.29% to $2.0 billion in 2024, then climbed by 11.82% to $2.3 billion in 2025, then declined by 8.33% to $2.1 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $2.1 billion (Q1 2026), $2.3 billion (Q4 2025), and $2.4 billion (Q3 2025), per Business Quant data.